Prostate cancer is the cancer that occurs in the male's prostate.
It is the most common cancer in men >50 years of age.
Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.
Chinese patients with metastatic castration-resistant prostate cancer (mCRPC) have higher response rates, longer survival and a lower risk of fatigue when enzalutamide is used in earlier rather than later lines of treatment, a study by the Hong Kong Society of Uro-Oncology has shown.
Adding docetaxel to androgen deprivation therapy (ADT) can prevent prostate-specific antigen (PSA) progression and delay the development of castration resistance in Chinese patients with metastatic hormone-naïve prostate cancer, a study by the Chinese University of Hong Kong (CUHK) has shown.
Researchers have developed a new polygenic hazard score, which has been validated by an independent dataset, for assessing personalized genetic risk that can predict age at onset of aggressive prostate cancer, reports a study.
Treatment with enzalutamide has maintained its antitumour activity in patients with hormone-naïve prostate cancer at 3 years, according to a recent study. In addition, overall bone mineral density, global health status and safety results are comparable to those at 2 years.
Compared with the anterior approach to the prostate, Retzius-sparing-robot-assisted radical prostatectomy is faster, allows a shorter catheterization time, and delivers better continence results at 4 weeks, with most patients being pad-free or needing just a single pad a day, a recent study has shown.
Enzalutamide, compared with bicalutamide, is effective in improving clinical outcomes regardless of age in chemotherapy-naïve men with metastatic castration-resistant prostate cancer, reports a recent study.
In Asian patients with localized prostate cancer, high dose rate (HDR) brachytherapy following an external beam radiotherapy (EBRT) achieves effective disease control while minimizing toxicity, a recent Singapore study has shown.
Preoperative biopsy Gleason grade (4 + 4 vs any Gleason pattern 5) subclassification of high-risk prostate cancer identifies men at highest risk for progression, according to a study. Furthermore, any Gleason 5 on biopsy correlates with a higher risk of metastasis, as well as prostate cancer-specific and overall mortality.
Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.